Athens Medical Centre (FRA:ACS) 3-Year RORE % : -1,633.33% (As of Dec. 2025)


FRA:ACS Athens Medical Centre SA FRA:ACS
68 GF Score
Price €1.62
GF Value €1.72
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Athens Medical Centre 3-Year RORE %?

Athens Medical Centre FRA:ACS 68 3-Year RORE % is -1,633.33 as of Dec. 2025. GuruFocus rates FRA:ACS with a GF Score™ of 68/100 and a GF Value™ of €1.72 (Fairly Valued). The stock has 8 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Athens Medical Centre ranks worse than 99.5% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Athens Medical Centre's 3-Year RORE % for the quarter that ended in Dec. 2025 was -1,633.33%.

The industry rank for Athens Medical Centre's 3-Year RORE % or its related term are showing as below:

FRA:ACS's 3-Year RORE % is ranked worse than
99.5% of 606 companies
in the Healthcare Providers & Services industry
Industry Median: 0.195 vs FRA:ACS: -1633.33

Athens Medical Centre  (FRA:ACS) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Athens Medical Centre 3-Year RORE % Related Terms


Athens Medical Centre 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Athens Medical Centre's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Athens Medical Centre 3-Year RORE % Chart

Athens Medical Centre Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.34 11.04 -25.63 -41.55 -1,633.33

Athens Medical Centre Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.63 -21.07 -41.55 -181.82 -1,633.33

FRA:ACS vs HCA, THC, DVA: 3-Year RORE % Comparison

For the Medical Care Facilities subindustry, Athens Medical Centre's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athens Medical Centre 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Athens Medical Centre's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Athens Medical Centre's 3-Year RORE % falls into.


FRA:ACS
68GF Score
Athens Medical Centre SA FRA:ACS
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Athens Medical Centre 3-Year RORE % Calculation

Athens Medical Centre's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.054-0.093 )/( 0.059-0.05 )
=-0.147/0.009
=-1,633.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -1,633.33 mean?
Athens Medical Centre (FRA:ACS) has a 3-Year RORE % of -1,633.33 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Athens Medical Centre and its competitors. According to the industry distribution chart, Athens Medical Centre ranks #603 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 99.5%.
Is Athens Medical Centre's 3-Year RORE % too high?
Athens Medical Centre's current 3-Year RORE % is -1,633.33. Based on the distribution chart, Athens Medical Centre ranks #603 out of 606 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Athens Medical Centre has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Athens Medical Centre's 3-Year RORE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Athens Medical Centre ranks #603 out of 606 companies for 3-Year RORE %. This places Athens Medical Centre in the lower half of its industry. The industry median 3-Year RORE % is 0.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Athens Medical Centre and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Athens Medical Centre's current 3-Year RORE % is -1,633.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Athens Medical Centre stock overvalued right now?
Based on GuruFocus' analysis, Athens Medical Centre (FRA:ACS) is currently considered Fairly Valued. The stock's GF Value™ is €1.72, compared to a current price of €1.62 — trading 5.8% below its estimated fair value. The current 3-Year RORE % is -1,633.33. Athens Medical Centre's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Athens Medical Centre (FRA:ACS), the current 3-Year RORE % is -1,633.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Athens Medical Centre (FRA:ACS) Overvalued in 2026?

Based on GuruFocus' analysis, Athens Medical Centre stock appears to be undervalued. The current stock price of €1.62 is trading 5.8% below its estimated GF Value™ of €1.72. GuruFocus considers Athens Medical Centre to be Fairly Valued.

Key valuation signals for FRA:ACS:

  • 3-Year RORE %: -1,633.33
  • GF Value™: €1.72 vs. price of €1.62 (5.8% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the FRA:ACS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Athens Medical Centre Business Description

Other Exchanges IATR:Greece
Address 5-7 Distomou Street Maroussi, Athens, GRC, 15125
Athens Medical Centre SA engages in the provision of healthcare services. It includes medical research and methods of treatment, training, and selection of executives and staff on behalf of the hospitals and importation of medical tools, instruments, machinery, and automated devices for the hospitals. Its offering includes medical services in such specializations as pathology, cardiology, general surgery, plastic and vascular surgery, orthopedic, physiotherapy, ophthalmology, urology, neurosurgery, thoracic, pediatric, dermatology, endocrinology and stomatology. The company operates in Domestic healthcare service, Healthcare service provided abroad (Romania) and Sale of medical tools & sanitary/health equipment segment.
68GF Score

Get the complete analysis for FRA:ACS

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price
€1.72
GF Value